GlobeNewswire Inc | Jul 8, 2021 08:00AM EDT

July 08, 2021

AUSTIN, Texas, July 08, 2021 (GLOBE NEWSWIRE) -- Aspira Womens Health Inc. (Nasdaq: AWH) today announced its OVA1 risk assessment test for ovarian cancer in women with pelvic masses is considered medically necessary according to AIM Specialty Healths Clinical Appropriateness Guidelines. AIM Specialty Health is a member of the Anthem Blue Cross Blue Shield family of companies and serves as a specialty benefits management company working with many of the nations largest health care organizations. AIMs mission is to promote appropriate, safe, and affordable health care. As one of the nations leading specialty benefits management firms, AIM helps improve the quality of care and reduces the cost for many of the most complex tests and treatments.

The OVA1 test is now included in AIMs guidelines for the preoperative evaluation of an adnexal mass when it is indeterminate based on clinical and complete pelvic ultrasound evaluation. The guidelines also include OVA1 for the determination of the required surgical approach, operator expertise and level of care for an adnexal mass.

Recent positive coverage additions for OVA1, such as New York State Medicaid, coupled with peer-reviewed publications documenting OVA1s superior clinical performance as compared to CA125, especially among Black women, has resulted in a dramatic increase in the number of women who have access to the OVA1 technology. Aspira Labs, Inc., a subsidiary of Aspira Womens Health, is the only U.S. provider for Aspiras proprietary OVA1 test, an FDA-cleared, ACOG recommended, and Medicare covered ovarian cancer risk assessment tool for women with a pelvic mass.

We are excited to provide access to OVA1plusTM, to such a large segment of the population, said Valerie Palmieri, President and CEO of Aspira Womens Health Inc. This guideline from an organization with a robust technology assessment process expands our ability to truly change the standard of care and helps advance our commitment to making OVA1 accessible to ALL women.

About Aspira Womens Health Inc.Aspira Womens Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming womens health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Womens Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1plusTM combines our FDA-cleared products, OVA1 and OVERA, to detect risk of ovarian malignancy in women with adnexal masses. [Aspira GenetiXTM] testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Womens Health is delivering a portfolio of pelvic mass products over a patients lifetime with our cutting-edge research. The next generation of products in development are [OVASightTM and EndoCheckTM]. Visit our website for more information at www.aspirawh.com.

Investor Relations Contact:Ashley R. Robinson LifeSci Advisors, LLC Tel 617-430-7577Arr@lifesciadvisors.com